<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2 )*
---------
NATIONAL QUALITY CARE, INC.
--------------------------------------------------------
(Name of Issuer)
Common Stock
--------------------------------------------------------
(Title of Class of Securities)
637269101
--------------------------------------------------------
(CUSIP Number)
Medipace Medical Group, Inc.,
Attn: Victor Gura, M.D.
5901 West Olympic Boulevard, Suite 300
Los Angeles, California 90036
(213) 935-5700
--------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
December 5, 1997
--------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box / /.
NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Continued on following page(s))
Page 1 of 15 Pages
---
<PAGE>
SCHEDULE 13D
CUSIP No. 637269101 Page 2 of 15 Pages
---------
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
S.S. or I.R.S. Identification Nos. of Above Person
Medipace Medical Group, Inc. (95-3915465)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) / /
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
State of California (USA)
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 800,000
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
0
--------------------------------------------------
(9) Sole Dispositive Power
800,000
--------------------------------------------------
(10) Shared Dispositive Power
0
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
800,000
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
/ /
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
8.37%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
SCHEDULE 13D
CUSIP No. 637269101 Page 3 of 15 Pages
---------
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
S.S. or I.R.S. Identification Nos. of Above Person
Victor Gura, M.D. (###-##-####)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) / /
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
USA
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 1,972,511
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
800,000
--------------------------------------------------
(9) Sole Dispositive Power
1,972,511
--------------------------------------------------
(10) Shared Dispositive Power
800,000
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
2,772,511
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
/ /
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
29.01%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
SCHEDULE 13D
CUSIP No. 637269101 Page 4 of 15 Pages
---------
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
S.S. or I.R.S. Identification Nos. of Above Person
Ronald P. Lang, M.D. (###-##-####)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) / /
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
USA
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 517,154
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
800,000
--------------------------------------------------
(9) Sole Dispositive Power
517,154
--------------------------------------------------
(10) Shared Dispositive Power
800,000
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
1,317,154
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
/ /
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
13.78%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
SCHEDULE 13D
CUSIP No. 637269101 Page 5 of 15 Pages
---------
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
S.S. or I.R.S. Identification Nos. of Above Person
Avraham H. Uncyk, M.D. (###-##-####)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) / /
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
USA
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 159,463
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
800,000
--------------------------------------------------
(9) Sole Dispositive Power
159,463
--------------------------------------------------
(10) Shared Dispositive Power
800,000
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
959,463
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
/ /
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
10.04%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
SCHEDULE 13D
CUSIP No. 637269101 Page 6 of 15 Pages
---------
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
S.S. or I.R.S. Identification Nos. of Above Person
Judith S. Gordon (###-##-####)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) / /
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
USA
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 159,463
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
800,000
--------------------------------------------------
(9) Sole Dispositive Power
159,463
--------------------------------------------------
(10) Shared Dispositive Power
800,000
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
959,463
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
/ /
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
10.04%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Page 7 of 15 Pages
NATIONAL QUALITY CARE, INC.
---------------------------
AMENDMENT NO. 2
TO
SCHEDULE 13D
Victor Gura, M.D., Ronald P. Lang, M.D., Avraham H. Uncyk, M.D.,
Judith S. Gordon and Medipace Medical Group, Inc.
January 7, 1998
1. SECURITY AND ISSUER.
Common Stock
National Quality Care, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
2. IDENTITY AND BACKGROUND.
VICTOR GURA, M.D.
a. Victor Gura, M.D.
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. Medical doctor (internal medicine/nephrology)
Medipace Medical Group, Inc.
5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
Los Angeles Community Dialysis, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
d. Not applicable
e. Not applicable
f. United States of America
<PAGE>
Page 8 of 15 Pages
RONALD P. LANG, M.D.
a. Ronald P. Lang, M.D.
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. Medical doctor (internal medicine/nephrology)
Medipace Medical Group, Inc.
5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
Los Angeles Community Dialysis, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
d. Not applicable
e. Not applicable
f. United States of America
AVRAHAM H. UNCYK, M.D.
a. Avraham H. Uncyk, M.D.
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. Medical doctor (internal medicine/endocrinology)
Medipace Medical Group, Inc.
5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
Los Angeles Community Dialysis, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
d. Not applicable
e. Not applicable
f. United States of America
<PAGE>
Page 9 of 15 Pages
JUDITH S. GORDON
a. Judith S. Gordon
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. Business Communications
Write It Right!
c/o Medipace Medical Group, Inc.
5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
d. Not applicable
e. Not applicable
f. United States of America
MEDIPACE MEDICAL GROUP, INC.
a. Medipace Medical Group, Inc.,
a California corporation
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. General family medical practice
d. Not applicable
e. Not applicable
f. California
3. SOURCES AND AMOUNT OF FUNDS OR OTHER CONSIDERATION; and
4. PURPOSE OF TRANSACTION.
On May 11, 1996, National Quality Care, Inc., f/k/a Sargent, Inc. ("NQCI"),
Los Angeles Community Dialysis, Inc. ("LACD"), Victor Gura, M.D. ("Gura"),
Avraham H. Uncyk, M.D. ("Uncyk") and Ronald P. Lang, M.D. ("Lang") completed the
transaction contemplated by an Agreement for the Exchange of Stock (the "Share
Exchange Agreement"), dated as of May 9, 1996. In connection with the Share
Exchange Agreement, NQCI issued an aggregate of 4,234,128 shares (the "Exchanged
NQCI Shares") of the common stock, par value $0.01 per share (the "Common
Stock") of NQCI to Gura, Uncyk and Lang in exchange for 100% of the issued and
outstanding shares (the "Exchanged LACD Shares") of common stock of LACD, as
follows: (i)Gura (2,183,036 shares), (ii) Lang (727,679 shares), (iii) Uncyk
(323,413 shares), and (iv) Medipace Medical Group, Inc.
<PAGE>
Page 10 of 15 Pages
("Medipace"), a California corporation owned by Gura, Lang and Uncyk
(1,000,000 shares). The 1,000,000 shares issued to Medipace were originally
issued to Gura, Lang and Uncyk in their proportionate ownership interests in
Medipace (67.5%, 22.5% and 10%, respectively), and subsequently transferred
to Medipace.
Prior to the completion of the Share Exchange Agreement, NQCI had issued
and outstanding 2,111,343 shares of Common Stock. At the closing (the
"Closing") of the Share Exchange Agreement, NQCI had 6,345,471 shares of Common
Stock issued and outstanding. As a result, the Exchanged NQCI Shares
constituted approximately 66.73% of the issued and outstanding shares of Common
Stock of NQCI at the Closing.
In connection with the Share Exchange Agreement, Gura Lang and Uncyk
became members of the Board of Directors of NQCI. On or about January 15, 1997,
Uncyk resigned as a director of NQCI, and Judith S. Gordon ("Gordon"), the
spouse of Uncyk, became a director of NQCI.
Further, up to an additional 4,210,644 shares of Common Stock for no
additional consideration and warrants to purchase up to 500,000 shares of Common
Stock at an exercise price of $3.50 per share may be issued in the aggregate to
Gura, Lang and Uncyk, on the following basis, in the event that NQCI meets
certain financial conditions based on the results of operations of NQCI as of
the end of the fiscal years ending December 31, 1997 through December 31, 2001:
(i) Gura (2,842,185 shares and 337,500 warrants), (ii) Lang (947,395 shares and
112,500 warrants), and (iii) Uncyk (421,064 shares and 50,000 warrants), which
reflects the percentage distribution ratio for the initial issuance of the
Exchanged NQCI Shares to Gura, Lang and Uncyk, respectively.
5. INTEREST IN SECURITIES OF THE ISSUER.
VICTOR GURA, M.D.
a. 2,772,511 shares (29.01%)
b. SOLE VOTING AND DISPOSITIVE POWERS - 1,972,511 shares
(See Item 4)
SHARED VOTING AND DISPOSITIVE POWERS - 800,000 shares
(See Items 2 and 6)
c. Not applicable
d. See Item 6
e. Not applicable
10
<PAGE>
Page 11 of 15 Pages
RONALD P. LANG, M.D.
a. 1,317,154 shares (13.78%)
b. SOLE VOTING AND DISPOSITIVE POWERS - 517,154 (See Item 6)
SHARED VOTING AND DISPOSITIVE POWERS - 800,000 shares (See Items 2 and
6)
c. Not applicable
d. See Item 6
e. Not applicable
AVRAHAM H. UNCYK, M.D.
a. 959,463 shares (10.04%)
b. SOLE VOTING AND DISPOSITIVE POWERS - 159,463 (See Item 6)
SHARED VOTING AND DISPOSITIVE POWERS - 800,000 shares (See Items 2 and
6)
c. Not applicable
d. See Item 6
e. Not applicable
JUDITH S. GORDON
a. 959,463 shares (10.04%)
b. SOLE VOTING AND DISPOSITIVE POWERS - 159,463 (See Item 6)
SHARED VOTING AND DISPOSITIVE POWERS - 800,000 shares (See Items 2 and
6)
c. Not applicable
d. See Item 6
e. Not applicable
MEDIPACE MEDICAL GROUP, INC.
a. 800,000 shares (8.37%)
b. SOLE VOTING AND DISPOSITIVE POWERS - 800,000 shares
SHARED VOTING AND DISPOSITIVE POWERS - none
c. Not applicable
d. See Item 6
e. Not applicable
<PAGE>
Page 12 of 15 Pages
Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
On or about November 25, 1997, Medipace, Gura, Lang and Uncyk
(collectively, the "Medipace Affiliates") sold an aggregate of 525,000 shares of
Common Stock at a gross per share sales price of $1.05 in connection with the
settlement of certain claims of an unaffiliated third party against such
persons, as follows: (i) Gura (202,500 shares), (ii) Lang (67,500 shares), (iii)
Uncyk (30,000 shares), and (iv) Medipace (200,000 shares).
As a result thereof, 600,000 shares of Common Stock registered in the name
of Medipace which were pledged as collateral and an additional 3,140,128 shares
of Common Stock collectively owned by Gura, Lang and Uncyk which were deposited
in escrow, and were subject to certain restrictions on transferability and
alienation until the obligations underlying such claims were paid in full, have
been released from such pledge and escrow arrangements.
Further, on or about December 5, 1997, in connection with the settlement of
certain claims by another unaffiliated third party, Gura, Lang and Uncyk sold an
aggregate of 285,000 shares of Common Stock at a gross per share sales of $1.05,
as follows: (i) Gura (8,025 shares), (ii) Lang (143,025 shares), and (iii) Uncyk
(133,950 shares).
Subsequent to the settlement of each of these claims and as of the date of
this Schedule 13D, the Medipace Affiliates are the registered owners of Common
Stock in the following amounts: (i) Gura (1,972,511 shares), (ii) Lang (517,154
shares), (iii) Uncyk (159,463 shares), and (iv) Medipace (800,000 shares). Each
of Gura, Uncyk and Lang are affiliates of Medipace and may be deemed to be the
beneficial owners of such shares. Gordon is the spouse of Uncyk and may be
deemed to be the beneficial owner of all shares beneficially owned by Uncyk.
Subsequent to the filing of Amendment No. 1 to the Schedule 13D, dated May
28, 1996: (i) 93,500 shares of Common Stock registered in the name of Medipace
were released from a pledge agreement with respect to certain claims by an
unaffiliated third party, and (ii) Lang and Uncyk were released from a proxy
previously granted to Gura with respect to the shares collectively owned by Lang
and Uncyk.
<PAGE>
Page 13 of 15 Pages
7. MATERIAL TO BE FILED AS EXHIBITS.
a. Agreement for Exchange of Stock, dated as of May 9, 1996
The Agreement for Exchange of Stock, dated as of May 9, 1996, which
constitutes an exhibit to this Schedule 13D, has been filed as an exhibit to the
Current Report on Form 8-K, dated May 24, 1996, as filed by the Company with the
Securities and Exchange Commission, and which document is incorporated herein by
this reference.
<PAGE>
Page 14 of 15 Pages
SIGNATURES
After reasonable inquiry and to the best of each of our knowledge, each of
the undersigned certifies that the information set forth in this statement is
true and correct as of January 7, 1998.
MEDIPACE MEDICAL GROUP, INC.
By: /s/ VICTOR GURA, M.D.
---------------------------
Victor Gura, M.D.
President
/s/ VICTOR GURA, M.D.
---------------------------
Victor Gura, M.D.
/s/ RONALD P. LANG, M.D.
---------------------------
Ronald P. Lang, M.D.
/s/ AVRAHAM H. UNCYK, M.D.
---------------------------
Avraham H. Uncyk, M.D.
/s/ JUDITH S. GORDON
---------------------------
Judith S. Gordon
<PAGE>
Page 15 of 15 Pages
INDEX TO EXHIBITS
SEQUENTIALLY
Exhibit Description of Document NUMBERED PAGE
------- ----------------------- -------------
A Agreement for Exchange of
Stock, dated May 9, 1996*
- -------------------------
* Previously filed as part of this Schedule 13D.
